Telling an adrenocortical carcinoma from a benign adenoma before surgery is still guesswork more often than clinicians would like; imaging cutoffs and hormone panels leave many adrenal masses indeterminate. Plasma untargeted metabolomics offers another kind of evidence. Writing in Frontiers in Pharmacology, Yang and colleagues profiled 153 samples and built a six-metabolite model that flagged carcinoma at an AUC of 0.9266. Key Takeaways A six-metabolite plasma panel separated

Clinical risk scores for type 2 diabetes already work well, which sets a high bar. A new biomarker panel has to beat age, BMI, family history and HbA1c before anyone pays to measure it. A multi-omics analysis of 42,840 UK Biobank participants, published in Cardiovascular Diabetology in May 2026, tested plasma proteomics, NMR metabolite profiling and a polygenic risk score against that benchmark over ten years and 1,090 incident cases. Which layer you add matters more than how

Dementia trials stall at the readout. Cognitive decline is slow to measure over the decade a cardiometabolic drug needs to prove itself. A post hoc analysis of the SELECT phase 3 trial took another route, using clinical proteomics to ask whether semaglutide 2.4 mg bends a validated 25-protein blood risk score across 104 weeks in 2,970 non-diabetic adults aged 65 and older. It did. Key Takeaways Semaglutide 2.4 mg slowed the two-year rise of a validated 25-protein blood dement

Gastric cancer is usually found late, and the blood tests meant to catch it early keep failing: CEA, CA19-9 and CA72-4 each miss roughly half of confirmed cases. A plasma metabolomics study published in Nature Communications in May 2026 asked whether small-molecule measurement could close that gap, using 1,706 participants from four Chinese centers. Three analytical stages ran in sequence, from untargeted discovery through relative quantitation to absolute quantitation, endin

Acute kidney injury has no approved disease-modifying drug, and the tissue where the injury program is visible, a kidney biopsy, is almost never available in routine care. A group writing in Inflammation attacked that gap with a multi-omics design running from human single-cell atlases down to a protein measurable in voided urine. Single-cell, bulk, and spatial transcriptomics were stacked against kidney proteomics from a mouse ischemia-reperfusion model and urine proteomics